Xeris has successfully completed two Phase 3 clinical studies of its investigational ready-to-use glucagon rescue pen (adult study: NCT02656069; pediatric study: NCT03091673). The company shared ...

The NDA included findings from multiple Phase 3 trials evaluating the safety, efficacy, and utility of the Xeris glucagon rescue pen auto-injector to treat severe hypoglycemia vs currently ...

Your doctor can prescribe an emergency glucagon kit. This contains the hormone in a powder and a syringe filled with fluid. It will have clear instructions on how to quickly mix and inject the ...

Glucagon is a hormone which helps to raise blood glucose levels. Always read the instructions of the kit carefully when using glucagon. When injected, glucagon is absorbed into the blood stream and ...

Gvoke (glucagon) is a prescription drug that ... or the vial and syringe kit, the instructions for use will differ. Each form is injected under the skin of your upper arm, stomach, or thigh ...

Austin-based specialty drug startup Xeris Pharmaceuticals just closed a $41 million Series C round to advance its G-Pen – a shelf-stable glucagon product for diabetics with severe hypoglycemia.

One of them that’s developed a low-volume formulation that’s stored in a two-step injectable glucagon pen is preparing for phase 2 clinical trials and looking for financing. Xeris ...

The US Food and Drug Administration (FDA) has approved a prefilled glucagon rescue pen (Gvoke HypoPen, Xeris Pharmaceuticals) for the treatment of severe hypoglycemia in adult and pediatric ...